

Research article

Open Access

## Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.

Karl Brillet<sup>1</sup>, Brigitte L Kieffer<sup>1,2</sup> and Dominique Massotte\*<sup>1,2</sup>

Address: <sup>1</sup>Département des Récepteurs et Protéines Membranaires, UPR 9050, Ecole Supérieure de Biotechnologie de Strasbourg, F-67400 Illkirch-Graffenstaden, France and <sup>2</sup>IGBMC, UMR 7104, F-67404 Illkirch-Graffenstaden cedex, France

Email: Karl Brillet - brillet@esbs.u-strasbg.fr; Brigitte L Kieffer - briki@igbmc.u-strasbg.fr; Dominique Massotte\* - massotte@igbmc.u-strasbg.fr

\* Corresponding author

Published: 01 December 2003

Received: 26 August 2003

BMC Pharmacology 2003, 3:14

Accepted: 01 December 2003

This article is available from: <http://www.biomedcentral.com/1471-2210/3/14>

© 2003 Brillet et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Background:** The concept of spontaneous- or constitutive-activity has become widely accepted and verified for numerous G protein-coupled receptors and this ligand-independent activity is also acknowledged to play a role in some pathologies. Constitutive activity has been reported for the mu opioid receptor. In some cases the increase in receptor basal activity was induced by chronic morphine administration suggesting that constitutive activity may contribute to the development of drug tolerance and dependence. Constitutively active mutants represent excellent tools for gathering information about the mechanisms of receptor activation and the possible physiological relevance of spontaneous receptor activity. The high basal level of activity of these mutants also allows for easier identification of inverse agonists, defined as ligands able to suppress spontaneous receptor activity, and leads to a better comprehension of their modulatory effects as well as possible *in vivo* use.

**Results:** Cysteines 348 and 353 of the human mu opioid receptor (hMOR) were mutated into alanines and Ala<sup>348,353</sup> hMOR was stably expressed in HEK 293 cells. [<sup>35</sup>S] GTPγS binding experiments revealed that Ala<sup>348,353</sup> hMOR basal activity was significantly higher when compared to hMOR, suggesting that the mutant receptor is constitutively active. [<sup>35</sup>S] GTPγS binding was decreased by cyprodime or CTOP indicating that both ligands have inverse agonist properties. All tested agonists exhibited binding affinities higher for Ala<sup>348,353</sup> hMOR than for hMOR, with the exception of endogenous opioid peptides. Antagonist affinity remained virtually unchanged except for CTOP and cyprodime that bound the double mutant with higher affinities. The agonists DAMGO and morphine showed enhanced potency for the Ala<sup>348,353</sup> hMOR receptor in [<sup>35</sup>S] GTPγS experiments. Finally, pretreatment with the antagonists naloxone, cyprodime or CTOP significantly increased Ala<sup>348,353</sup> hMOR expression.

**Conclusion:** Taken together our data indicate that the double C348/353A mutation results in a constitutively active conformation of hMOR that is still activated by agonists. This is the first report of a stable CAM of hMOR with the potential to screen for inverse agonists.

## Background

The opioid receptors and endogenous opioid peptides form a neuromodulatory system that plays a major role in the control of nociceptive pathways. The opioid system also modulates affective behavior, neuroendocrine physiology, and controls autonomic functions such as respiration, blood pressure, thermoregulation and gastrointestinal motility. The receptors are targets for exogenous narcotic opiate alkaloids that constitute a major class of drugs of abuse [1]. Genes coding for  $\delta$ ,  $\kappa$  and  $\mu$  opioid receptor types have been identified and isolated from different vertebrates. Analysis of their sequences shows that the receptors belong to the G protein-coupled receptor (GPCR) superfamily. The three opioid receptor types exhibit different pharmacological profiles but all three mediate their cellular effects by first activating heterotrimeric G-proteins of the inhibitory type that negatively couple to adenylyl cyclase.

The delta opioid receptor was the first GPCR described as able to modulate second messengers in the absence of an agonist [2]. To date the concept of spontaneous- or constitutive-activity has become widely accepted and verified for numerous GPCRs [2-5], and this ligand-independent activity is also suggested to play a role in some pathologies [6]. For opioid receptors, constitutive activity has now been reported not only for the delta [7-11] but also for the kappa [12] and mu opioid receptors. In this latter case, constitutive activity arose from spontaneous coupling to endogenous G proteins [13,14] or was induced by chronic morphine administration [15,16]. Some ligands like naloxone and naltrexone were shown to act as antagonists in untreated cells and to display inverse agonist properties following morphine pretreatment [14-16]. Detection of enhanced basal activity for mu opioid receptor densities as low as 150 fmol/mg protein suggested that this activity is of physiological relevance and may be involved in the mechanisms underlying opioid tolerance [14].

Receptor mutagenesis has been widely used to probe receptor activation mechanisms. Interestingly, some mutations appeared to enhance basal activities of GPCRs. Such mutations are believed to mimic agonist activity and favor the active state of the receptor, thus facilitating productive interaction with intracellular G proteins. These mutant receptors are currently called Constitutively Active Mutants (CAM) and exhibit several remarkable characteristics [17-22]: (1) enhanced basal signaling activity, (2) increased affinity for agonists, (3) enhanced agonist potency and (4) increased level of expression upon cell treatment with antagonists or inverse agonists. Several CAMs have been described for the delta opioid receptor [23-25]. Recently two mutants were also reported for the mu opioid receptor. However both D164Q [26,27] and T279K [28] mutations resulted in highly unstable mu

receptors that required addition of naloxone for stabilization and detection of ligand binding.

In this work we characterized a mutant of the human mu opioid receptor in which cysteine residues 348 and 353 were replaced by alanines. The resulting protein was stably expressed in HEK 293 cells at a pmol/mg membrane protein level and exhibited all the characteristics of a constitutively active mutant. Its potential use to screen for inverse agonists was also established.

## Results

### Construction and stable expression of Ala<sup>348,353</sup> hMOR in HEK 293 cells

We replaced cysteines 348 and 353 with alanine residues in the human mu opioid receptor (hMOR). Alanine residues were preferred over serines to avoid introduction of additional potential phosphorylation sites in the C-terminal part of the receptor. Wild-type hMOR and the Ala<sup>348,353</sup> hMOR mutant were stably expressed in HEK 293 cells and compared.

Scatchard analysis indicated that both hMOR and Ala<sup>348,353</sup> hMOR displayed similar K<sub>d</sub> values for the antagonist diprenorphine (Table 1) and that maximal expression levels were  $1.50 \pm 0.20$  pmol/mg membrane protein for Ala<sup>348,353</sup> hMOR and  $4.13 \pm 0.26$  pmol/mg membrane protein for the wild-type hMOR. Addition of a ligand in the culture medium was not required to reach and maintain the high Ala<sup>348,353</sup> hMOR expression level nor did this level vary significantly with time for up to several months of culture, corresponding to at least 25 passages.

### Enhanced basal [<sup>35</sup>S] GTP $\gamma$ S incorporation in Ala<sup>348, 353</sup> hMOR

Data collected on several clones expressing hMOR or Ala<sup>348,353</sup> hMOR demonstrated that the double mutant exhibited higher level of spontaneous [<sup>35</sup>S] GTP $\gamma$ S incorporation when compared to hMOR ( $25 \pm 2$  fmol/mg and  $41 \pm 2.5$  fmol/mg respectively, Student's *t* test  $p < 0.001$ ) (Table 2). Moreover, since the expression level of Ala<sup>348,353</sup> hMOR was approximately three times lower than the wild-type receptor, these results strongly suggest that the mutant is a CAM receptor. We further investigated [<sup>35</sup>S] GTP $\gamma$ S binding to probe the associated G proteins. Coupling of opioid receptors is known to proceed through inhibitory G $\alpha$  proteins either pertussis toxin (PTX) sensitive (G<sub>i/o</sub>) or insensitive (G<sub>z</sub>), the latter type being absent from HEK 293 cells [29]. PTX treatment abolishes interaction between the receptor and inhibitory G<sub>i/o</sub> $\alpha$  proteins by ADP ribosylation of a C-terminal cysteine residue on the G $\alpha$  protein. Following PTX treatment, the [<sup>35</sup>S] GTP $\gamma$ S basal level of incorporation for hMOR was reduced to the level observed in untransfected HEK 293 cells (Figure 1A), denoting some spontaneous

**Table 1: Binding affinities for hMOR and Ala<sup>348,353</sup> hMOR stably expressed in HEK 293 cells. Competition experiments were as described in the Experimental Procedures. Data are given as the mean ± S.E.M. from at least 3 independent experiments performed in triplicate. Statistical analysis was performed using Student's t test: the asterisks (\*p < 0.05) refer to Ki values significantly different from corresponding Ki values for hMOR.**

Ligand	hMOR	Ala <sup>348,353</sup> hMOR	K <sub>i</sub> <sup>Ala 348,353hMOR</sup> /K <sub>i</sub> <sup>hMOR</sup>
	Ki(nM)	Ki(nM)	
Diprenorphine (Kd)	0.21 ± 0.03	0.41 ± 0.04	
DAMGO	3.60 ± 0.44	1.13 ± 0.53*	0.32
Dermorphin	4.10 ± 1.70	0.26 ± 0.10*	0.06
Morphine	18.87 ± 4.76	0.88 ± 0.06*	0.05
β-endorphin	1.35 ± 0.42	2.45 ± 1.01	1.81
Dynorphin A	4.12 ± 0.85	1.59 ± 0.86	0.39
Met-enkephalin	2.78 ± 0.12	2.53 ± 0.58	0.91
Endomorphin 1	8.73 ± 2.66	0.51 ± 0.17*	0.06
Endomorphin 2	11.70 ± 3.90	1.79 ± 0.83*	0.15
Naloxone	3.63 ± 1.45	0.99 ± 0.25	0.27
Naltrexone	0.55 ± 0.22	0.17 ± 0.01	0.31
Naltrindole	5.07 ± 0.58	5.42 ± 0.56	1.06
Naloxonazine	2.91 ± 0.97	1.06 ± 0.23	0.36
Nalbuphine	2.28 ± 0.79	0.66 ± 0.05	0.29
CTOP	5.46 ± 0.70	0.32 ± 0.05*	0.06
Cyprodime	23.12 ± 7.22	1.83 ± 0.40*	0.08


**Table 2: Efficacy and potency of opioid agonists for the stimulation of [<sup>35</sup>S] GTPγS binding in HEK 293 cells stably expressing hMOR or Ala<sup>348,353</sup> hMOR. Agonist efficacy was calculated as the maximal difference between specific [<sup>35</sup>S] GTPγS binding in the presence and absence of agonist and is expressed in fmol/mg. EC<sub>50</sub> values were obtained from curve fitting of dose response curves shown in Figure 3. Receptor densities were 4.13 ± 0.26 and 1.5 ± 0.20 pmol/mg membrane protein for hMOR and Ala<sup>348,353</sup> hMOR, respectively. Statistical analysis was performed using Student's t test: the asterisks (\*\*p < 0.01, \*\*\*p < 0,001) refer to values significantly different from corresponding values for hMOR (Student's t test,)**

	Basal	DAMGO	Morphine
	fmol/mg	Efficacy fmol/mg	EC <sub>50</sub> nM
hMOR	25 ± 2 (n = 32)	98 ± 10 (n = 10)	81 ± 2 (n = 5)
Ala <sup>348,353</sup> hMOR	41 ± 2.5*** (n = 18)	58 ± 6 *** (n = 9)	9.1 ± 2.4** (n = 4)
			Efficacy fmol/mg
			EC <sub>50</sub> nM
			48 ± 7 (n = 3)
			48 ± 5 (n = 4)
			176 ± 2 (n = 3)
			60 ± 2** (n = 4)

coupling of the wild-type receptor to endogenous G<sub>i/o</sub> α proteins under our experimental conditions. The high [<sup>35</sup>S] GTPγS basal level of activity observed for the double mutant was also reduced by PTX treatment though not to the level observed in untransfected HEK 293 cells, suggesting that spontaneous coupling of the mutant receptor might also be mediated via PTX-insensitive Gα proteins (Figure 1A) (see discussion). DAMGO-stimulated [<sup>35</sup>S] GTPγS incorporation was completely abolished by PTX treatment for both the wild type and the double mutant as expected for receptors coupled to G<sub>i/o</sub> α proteins (Figure 1B).

**Pharmacological profile of Ala<sup>348,353</sup> hMOR**

CAM receptors are generally characterized by increased agonist binding affinity while antagonist binding affinity remains unaltered [17,18,20,21]. Consistent with this, binding affinities of most agonists tested were increased for Ala<sup>348,353</sup> hMOR when compared to hMOR. Interestingly, morphine and dermorphin affinities were increased approximately 20-fold while we found no significant change in affinities for the three endogenous peptides dynorphin A, met-enkephalin and β-endorphin (Table 1). On the other hand, binding affinities of several ligands previously described as antagonists remained virtually



**Figure 1**  
**Comparison of hMOR and Ala<sup>348,353</sup> hMOR [<sup>35</sup>S] GTPγS binding with or without PTX treatment.** Basal (panel A) and DAMGO-induced (panel B) [<sup>35</sup>S] GTPγS incorporation were measured as described in the Experimental Procedures. Membranes were prepared from HEK 293 cells stably expressing hMOR or Ala<sup>348,353</sup> hMOR. Cells were treated with 100 ng/mL PTX for 20 h where indicated. DAMGO was added at a concentration of 10 μM. Data are given as the mean ± S.E.M. from at least 3 independent experiments performed in triplicate. Statistical analysis was performed using Student's t test to evaluate the effects of mutation (\*\*\*, p < 0.001) or PTX-treatment (##, p < 0.01) on basal [<sup>35</sup>S] GTPγS incorporation (panel A) and of the effect of PTX-treatment (\*\*, p < 0.01) on DAMGO-induced [<sup>35</sup>S] GTPγS incorporation (panel B).

unchanged while we observed at least a 10-fold increase in affinity for the antagonists CTOP and cyprodine (Table 1). Interpretation for this latter observation remains uncertain. Therefore modifications of ligand binding, classically described for CAM receptors, were verified for most, but not all opioid compounds.

#### **Increased potency of agonist stimulated [<sup>35</sup>S] GTPγS incorporation**

We measured [<sup>35</sup>S] GTPγS incorporation and determined the EC<sub>50</sub> values for DAMGO and morphine as prototypic full and partial agonists, respectively (Table 2). EC<sub>50</sub> values for Ala<sup>348,353</sup> hMOR were decreased almost 10-fold for DAMGO (9.1 ± 2.4 nM versus 81 ± 2 nM) and 3-fold for morphine (60 ± 2 nM versus 176 ± 2 nM). These data demonstrate that agonist potency is increased, as observed for other CAM GPCRs [17,20]. DAMGO-induced maximal [<sup>35</sup>S] GTPγS incorporation was considerably lower at Ala<sup>348,353</sup> hMOR than the wild-type receptor while morphine activated Ala<sup>348,353</sup> hMOR and hMOR to a similar extent (Table 2). When expressed as a percentage of stimulation above basal levels (Figure 2), the maximal efficacy of both ligands was reduced when compared to hMOR (respectively 164 ± 6% versus 366 ± 23% for DAMGO and 164 ± 5% versus 205 ± 9% for morphine) due to the higher basal activity level of the double mutant. Moreover, the lower level of expression of the mutant receptor could also contribute to this observation since it directly affects the extent of [<sup>35</sup>S] GTPγS incorporation [23]. Taken together these results indicate that Ala<sup>348,353</sup> hMOR is activated by agonists and that the extent of activation seems to be ligand dependent.

#### **Inverse agonism at Ala<sup>348,353</sup> hMOR**

Elevated basal activity of the receptors allows compounds to be tested for intrinsic negative activity, also called inverse agonism [5,6,30]. In order to identify ligands with inverse agonist properties, several antagonists were tested for their ability to decrease the basal level of [<sup>35</sup>S] GTPγS incorporation on the Ala<sup>348,353</sup> mutant. Under our experimental conditions, all the tested compounds had statistically significant (Student's *t* test, *p* < 0.05) partial agonist activity on hMOR with the exception of naloxone and naltrexone (Figure 3A). Partial agonist activity has been observed for several opioid ligands originally described as antagonists such as cyprodime [31], CTAP [14], TIPP and Tic-deltorphine (Kieffer B.L. unpublished) as well as for 5HT<sub>4</sub> ligands [32]. In contrast, this partial agonist activity was not observed with Ala<sup>348,353</sup> hMOR. Moreover cyprodime and CTOP significantly reduced the level of basal activity of Ala<sup>348,353</sup> hMOR (89 ± 3% and 77 ± 5% of control respectively, Student's *t* test *p* < 0.01). The EC<sub>50</sub> values were 93 ± 3 nM and 64 ± 3 nM for CTOP and cyprodime respectively (data not shown). These data sug-


gest that both ligands possess intrinsic inverse agonist activity that is revealed at the CAM receptor (Figure 3B).

#### **Upregulation of Ala<sup>348,353</sup> hMOR expression**


Addition of inverse agonists or antagonists to the cell culture medium was reported to increase the level of expression of CAM GPCRs by stabilizing their conformation [19,20,27]. We therefore examined the effect of naloxone, CTOP and cyprodime on the levels of expression of hMOR and Ala<sup>348,353</sup> hMOR. Expression levels measured on intact cells using [<sup>3</sup>H] diprenorphine were 243 000 ± 28 000 receptors/cell for Ala<sup>348,353</sup> hMOR and 546 000 ± 103 000 receptors/cell for hMOR prior treatment. Naloxone and CTOP slightly increased hMOR expression levels (145 ± 11% and 157 ± 20% respectively) while cyprodime had no effect (103 ± 9%). In contrast Ala<sup>348,353</sup> hMOR expression level was enhanced more than 2-fold in the presence of alkaloid antagonists (257 ± 19% with naloxone and 245 ± 20% with cyprodime, see Figure 4). Importantly K<sub>d</sub> values for [<sup>3</sup>H] diprenorphine were not significantly altered by the various treatments (data not shown). Therefore, although basal expression of the mutant receptor is high, opioid antagonists increased the number of receptors as previously observed for other CAM GPCRs [19,20,27]. On the other hand, CTOP treatment increased both mutant (182 ± 4%) and wild type receptor (157 ± 20%) expression levels but failed to induce a significantly higher expression level for Ala<sup>348,353</sup> hMOR as compared to the wild type receptor (Figure 4, see discussion). Receptor up-regulation by naloxone and cyprodime was detectable using intact cells treated for 48 hours and was also observed on membranes prepared from these cells (data not shown).

#### **Chronic treatment with morphine**

Finally, because chronic morphine treatment was reported to increase basal activity of mu receptors in HEK 293 [33] and GH3 [16] cells, we treated our HEK 293 cells stably expressing hMOR or Ala<sup>348,353</sup> hMOR with 10 μM morphine for 48 h. Under our experimental conditions, morphine pretreatment did not modify the basal level of [<sup>35</sup>S] GTPγS incorporated in hMOR or Ala<sup>348,353</sup> hMOR. Moreover, we could not detect any increase of the maximal inverse agonist efficacy of CTOP and cyprodime following chronic morphine treatment of cells expressing either hMOR or Ala<sup>348,353</sup> hMOR (data not shown). A possible explanation for this discrepancy could be a combination of factors such as cell type (HEK 293 cells versus GH3 cells), duration of morphine exposure (48 h versus 16 h in HEK 293 cells) and a lack of sensitivity of the detection method ([<sup>35</sup>S] GTPγS performed on crude membrane preparation without prior G protein isolation). Nevertheless, in agreement with previous reports, we observed a significant reduction of [<sup>35</sup>S] GTPγS incorporation following DAMGO stimulation for both hMOR (339 ±



**Figure 2**  
**DAMGO and morphine-stimulated [<sup>35</sup>S] GTP<sub>γ</sub>S binding at hMOR and Ala<sup>348,353</sup> hMOR.** Increasing concentrations of DAMGO and morphine (10<sup>-10</sup> to 10<sup>-4</sup> M) were used to stimulate [<sup>35</sup>S] GTP<sub>γ</sub>S binding. Panel A: DAMGO at hMOR (■) or at Ala<sup>348,353</sup> hMOR (▼). Panel B: morphine at hMOR (◆) or Ala<sup>348,353</sup> hMOR (▲). Data are given as the mean ± S.E.M. from at least 3 independent experiments performed in triplicate.



**Figure 3**  
**Effect of antagonists on the incorporation of [<sup>35</sup>S] GTP<sub>γ</sub>S binding in membranes expressing hMOR and Ala<sup>348,353</sup> hMOR.** [<sup>35</sup>S] GTP<sub>γ</sub>S incorporation was measured as described in the Experimental Procedures. Panel A: membranes prepared from HEK 293 cells stably expressing hMOR. Panel B: membranes prepared from HEK 293 cells stably expressing Ala<sup>348,353</sup> hMOR. All ligands were used at a concentration of 10 μM. Incorporation is expressed as percent variation over [<sup>35</sup>S] GTP<sub>γ</sub>S binding in the absence of agonist. Data are given as the mean ± S.E.M. from 3 (except naloxone, CTOP and cyprodime where n = 5) independent experiments performed in triplicate. Statistical analysis was performed using Student's t test, \*p < 0.05, \*\*p < 0.01 compared to basal [<sup>35</sup>S] GTP<sub>γ</sub>S.

16% versus  $425 \pm 26\%$ , Student's *t* test  $p < 0.05$ ) and Ala<sup>348,353</sup> hMOR ( $120 \pm 5\%$  versus  $153 \pm 13\%$ , Student's *t* test  $p < 0.05$ , data not shown) presumably reflecting receptor desensitization [16,33].

## Discussion

In this paper, we describe a mutant of the human mu opioid receptor in which cysteine residues 348 and 353 have been replaced by alanines and we demonstrate that this mutant receptor is constitutively active, based on characteristic properties previously described for other CAM GPCRs.

The most decisive criterion used to define a CAM receptor is enhanced basal activity. Ala<sup>348,353</sup> hMOR exhibited basal [<sup>35</sup>S] GTP $\gamma$ S incorporation at least 1.5 times higher than wild-type hMOR under conditions where the mutant receptor was expressed at levels almost three times lower than the wild-type receptor. This strongly indicates that the Ala<sup>348,353</sup> mutant spontaneously activates G proteins more efficiently than the wild-type receptor, and is further supported by the PTX sensitivity of this activity. Noticeably, for the Ala<sup>348,353</sup> hMOR mutant, PTX treatment did not entirely reduce basal [<sup>35</sup>S] GTP $\gamma$ S incorporation to the level observed in non-transfected cells. One explanation could be that the mutant receptor is partially coupled to the inhibitory PTX-insensitive G<sub>z</sub> $\alpha$  protein, as previously shown for mu receptors [29]. G<sub>z</sub> $\alpha$  subunits, however, appear to be absent in HEK 293 cells [29]. Alternatively, one may speculate that the constitutive conformation of the mutant receptor may exhibit broader G protein selectivity allowing it to interact with G $\alpha$  subunits for which coupling remains to be established. This could be of importance if chronic administration of drugs does indeed increase basal activity of the mu receptor [16,33]. A residual [<sup>35</sup>S] GTP $\gamma$ S incorporation following PTX treatment could also be observed for the CAM T279K mu receptor [28].

CAMs generally display enhanced agonist binding affinity, supposedly because a large fraction of the receptors are in a G protein-precoupled active state [20,21]. Ala<sup>348,353</sup> hMOR satisfied this criterion for most of the ligands tested. One notable exception was the modest changes in affinity showed by the endogenous opioid peptides compared to alkaloids or synthetic peptides. Dynorphin A showed only a tendency to an increase in binding affinity for Ala<sup>348,353</sup> hMOR, while  $\beta$ -endorphin and met-enkephalin affinities remained unchanged. Interestingly, in another set of experiments, we forced receptor interaction with G $\alpha$  proteins by fusing hMOR to G<sub>11</sub> $\alpha$  or G<sub>12</sub> $\alpha$ . As expected, binding affinities were increased for most agonists. However,  $\beta$ -endorphin and met-enkephalin affinities remained unchanged while dynorphin A affinity increased for the G<sub>12</sub> $\alpha$ -hMOR fusion only [34]. Endog-


enous opioid peptides, therefore, could be less sensitive to the coupling status of the receptor compared to other exogenous or synthetic opioids. An implication of this observation is that the putative modifications of mu opioid receptor coupling following chronic morphine suggested by some authors [16,33], may be of little consequence to endogenous opioid binding.

Because of its high stable expression and CAM properties, Ala<sup>348,353</sup> hMOR represents a unique tool for identification of compounds with inverse agonist properties. Our analysis of a number of mu receptor antagonists revealed, for the first time, negative functional activity for CTOP and cyprodime (see Figure 3B). Previous studies suggested that the irreversible antagonist  $\beta$ -CNA could inhibit the spontaneous activity of the wild-type mu opioid receptor [13]. Also inverse agonist properties were reported for  $\beta$ -CNA as well as naloxone and naltrexone following chronic exposure to opioid agonists [14,16]. Our data highlight two novel antagonists as mu opioid inverse agonists, and more will likely be discovered in the future.

Both DAMGO and morphine exhibited enhanced potency for Ala<sup>348,353</sup> hMOR as expected for agonists interacting with a CAM. Enhanced potency to stimulate [<sup>35</sup>S] GTP $\gamma$ S binding can be correlated to the higher affinity observed for both agonists towards the Ala<sup>348,353</sup> mutant receptor. Higher potency for agonists has also been described for CAMs of  $\alpha_{1a}$ -,  $\alpha_{1b}$ -[17,20] as well as  $\alpha_{2A}$ -adrenergic [21] or  $\beta_2$ -adrenergic receptors [18] and, more recently, for a CAM of the 5-HT<sub>4(a)</sub> receptor [35]. Interestingly, all agonists tested increased ERK2 (p44) phosphorylation upon binding to Ala<sup>348,353</sup> hMOR to levels higher than the wild type receptor, suggesting that the double Ala 348, 353 Cys mutation alters both G $\alpha$ - and G $\beta\gamma$ -dependent signaling pathways (data not shown).

Enhancement of expression levels following receptor exposure to a ligand is another typical feature of CAM GPCRs. Accordingly, Ala<sup>348,353</sup> hMOR was significantly upregulated upon naloxone or cyprodime treatment. Interestingly, however, basal expression of the Ala<sup>348,353</sup> hMOR receptor was relatively high and easily detectable in the absence of any ligand in the culture medium. Structural instability seems to be a frequent characteristic of CAMs, but this was not obvious in our case. Two CAMs of the mu opioid receptor were reported previously, with D164Q [26,27] and T279K [28] mutations located in the transmembrane domains III and VI, respectively. Both mutants are highly unstable and require the presence of the antagonist naloxone in the cell culture medium for stabilization and pharmacological detection [27,28]. One explanation for the relative stability of Ala<sup>348,353</sup> hMOR may lie in the C-terminal location of the mutations downstream from helix VIII that is postulated on the basis of





**Figure 4**

**Upregulation of hMOR and Ala<sup>348,353</sup>hMOR expression upon ligand pretreatment of the cells.** Saturation experiments using [<sup>3</sup>H]diprenorphine on intact HEK 293 cells stably expressing hMOR (checked bars) or Ala<sup>348,353</sup>hMOR (black bars) following cell treatment with naloxone, cyprodime or CTOP 1 mM for 48 h as described in the Experimental Procedures. Data are given as the mean ± S.E.M. from at least 4 independent experiments. Statistical analysis was performed using Student's *t* test to compare upregulation at wild-type and mutant receptors, \*\* *p* < 0.01 compared to hMOR.

alignment with the rhodopsin three-dimensional structure [36]. The mutated cysteines are not likely to be directly involved in the formation of the ligand binding pocket or critical in maintaining the three-dimensional architecture of the helical protein core. Ala<sup>348,353</sup>hMOR expression was nevertheless upregulated upon cell treatment with naloxone, cyprodime or CTOP. According to the extended ternary complex model, CAMs are expected to favor the partially activated receptor state (R\*) that is very often unfavorable in terms of energy and results in some structural instability [19,37]. Antagonists as well as inverse agonists on the other hand bind preferentially to

the inactive R state of the receptor and stabilize it. Therefore the increased number of double mutant receptors observed following naloxone, cyprodime or CTOP treatment may reflect the shift of the equilibrium towards the R form resulting in a larger proportion of structurally more stable receptors. However it could also reflect the blocking of constitutive internalization and down regulation as suggested for the D164Q mutant [27] and observed for the wild-type hMOR [27,38]. Interestingly, CTOP treatment increased Ala<sup>348,353</sup>hMOR expression level to a lesser extent than either naloxone or cyprodime. Also the mutant receptor expression level following CTOP

treatment was not significantly higher than the one observed for the wild-type receptor. This is in contrast with the larger number of Ala<sup>348,353</sup> hMOR receptors detected following treatment with the membrane permeable alkaloids naloxone and cyprodime compared to wild type. These results suggest that stabilization, by alkaloids, of a receptor folding intermediate during its transport to the plasma membrane may also contribute to the upregulation of expression observed for the double mutant. Indeed such a chaperone activity resulting in an increased cell surface expression of rat mu opioid receptor mutants was recently reported [39]. Moreover proper folding of the polypeptide has been demonstrated to be of crucial importance for cell surface expression in several cases [40] including the human delta opioid receptor expressed in HEK 293 cells [41].

Mutations of the C-terminal cysteine residues have already been reported for several GPCRs [35,42-44]. At present the influence of C-terminal cysteine mutations on the signaling efficiency seems receptor type-dependent [35,42-44]. Mutation of the conserved cysteine residues 328/329 into serines in the 5-HT<sub>(4a)</sub> receptor, a receptor coupled to G<sub>s</sub>α, led to a CAM [35]. Using a random mutagenesis screen a delta opioid receptor mutant in which cysteine 328 was replaced by an arginine residue was recently identified as having constitutive activity [25]. Ala<sup>348,353</sup> hMOR is the third example of a receptor mutant whose constitutive activity is intertwined with C-terminal cysteine replacement. The two cysteine residues mutated in hMOR are located in well conserved positions (cysteine 353 is conserved in the 5-HT<sub>4a</sub> receptor and cysteine 348 is equivalent to cysteine 328 in the delta opioid receptor) suggesting a common role at least in some GPCRs. The mechanism underlying the appearance of constitutive activity has been correlated with the palmitoylation state of the cysteine residues in the case of the 5-HT<sub>(4a)</sub> receptor [35] and preliminary data indicate that hMOR is palmitoylated when expressed in baculovirus-infected Sf9 cells (Massotte D., unpublished results). However other explanations can be envisaged that would involve the dynamic regulation of the receptor such as a mutation-induced modulation of its phosphorylation state [45]. We are currently further investigating the cysteine residue(s) responsible for Ala<sup>348,353</sup> hMOR constitutive activity as well as the underlying mechanisms.

## Conclusions

We have established that the mutation of cysteines 348 and 353 into alanines resulted in a mutant hMOR receptor whose conformation satisfies criteria known to define a CAM. This is also the first mutant of this type described for the mu opioid receptor that does not require the addition of a ligand to the culture medium to be stably expressed at a pmol/mg membrane protein level. These

combined properties suggest that this mutant receptor is of potential use for inverse agonist screening. This is indeed the case since Ala<sup>348,353</sup> hMOR high basal activity led for the first time to the identification of CTOP and cyprodime as inverse agonists and will undoubtedly trigger the discovery of others. Identification of such ligands offers new tools to probe the spontaneous activity of the wild-type mu opioid receptor upon chronic administration of drugs. This CAM also provides an interesting model that mimics spontaneous receptor activity and could help to address the mechanisms underlying the development of drug tolerance and dependence.

## Methods

### Materials

[<sup>3</sup>H] Diprenorphine was purchased from Amersham (Arlington Heights, IL, USA) and [<sup>35</sup>S] GTPγS (specific activity 1250 Ci/mmol) from Perkin Elmer Life Science (Boston, Ma, USA). Ligands were from Sigma (St Louis, MO, USA). All materials for tissue culture were supplied by Life Technologies, Inc. (Paisley, U.K).

### Construction of the mutated receptor

The cDNA encoding the human mu opioid receptor in pcDNA3 was used as a template to generate a mutant in which C348A and C353A mutations were introduced using PCR. The oligonucleotide A containing a *Kpn*I site (underlined) 5'-ATTGGGGTACCCCATGGACAGCAGCGCTGCC-3' and the oligonucleotide 5'-GAACTCTCTGAAGGCTCGTTTGAA-3' were used to generate the C348A mutation. The oligonucleotide 5'-TTCA-GAGAGTTCGCTATCCCAA-3' and the oligonucleotide B containing a *Kpn*I site (underlined) 5'-CTCGGGTACCT-TAGGGCAACGGAGCAGTTTCTGC-3' were used to generate the C353A. The resulting PCR products were used as templates for a second amplification by PCR using oligonucleotides A and B to generate the double mutant Ala<sup>348,353</sup> hMOR that was introduced in the *Kpn*I site of pcDNA3 and verified by sequencing.

### Cell culture and generation of stable cell lines

HEK 293 cells were maintained in MEM containing 10% (v/v) fetal calf serum and 2 mM glutamine. Cells plated in 10 cm<sup>2</sup> dishes at semi-confluence were transfected with hMOR, or Ala<sup>348,353</sup> hMOR using calcium phosphate coprecipitation. Individual clones were isolated and expanded in the presence of 100 μg/mL geneticin. Where indicated, cells were treated with 100 ng/ml PTX for 20 h before harvesting.

### Receptor expression following cell treatment with antagonists

HEK 293 cells stably expressing hMOR or Ala<sup>348,353</sup> hMOR were treated with 1 μM naloxone, cyprodime or CTOP for 48 h with one medium exchange after 24 h. Cells were

then washed three times with PBS containing 320 mM sucrose, resuspended in 50 mM Tris, pH 7.4 containing 320 mM sucrose and counted. Saturation analysis was performed on intact cells under conditions similar to those described for membranes (see below). 0.2% BSA was added to all buffers when CTOP-treated cells were used.

#### Preparation of membranes

Cells were collected, washed twice with PBS and stored at  $-80^{\circ}\text{C}$  in PBS containing 320 mM sucrose. Cell pellets were resuspended in ice cold 50 mM Tris-HCl, 1 mM EDTA, pH 7.4, disrupted using a glass homogenizer and centrifuged at 2000 g for 10 min. The pellet was homogenized in ice cold 50 mM Tris-HCl, 1 mM EDTA, pH 7.4 and centrifuged at 1000 g for 5 min. Both supernatants were combined and ultracentrifuged at 100 000 g for 40 min at  $4^{\circ}\text{C}$ . The pellet was resuspended in 50 mM Tris-HCl, 1 mM EDTA, 320 mM sucrose, pH 7.4 then homogenized through a 26-gauge needle and stored in aliquots at  $-80^{\circ}\text{C}$  before use.

#### Saturation and competition analysis

For each assay 10  $\mu\text{g}$  of membrane protein was incubated in 50 mM Tris-HCl, pH 7.4 with the appropriate ligands in a final volume of 500  $\mu\text{l}$  for 30 min at  $22^{\circ}\text{C}$ . For all saturation experiments [ $^3\text{H}$ ] diprenorphine was used in a 0.05–6.4 nM range and naloxone was used at 2  $\mu\text{M}$  to determine non-specific binding. For all competition experiments [ $^3\text{H}$ ] diprenorphine was used at 1 nM and the competing ligand in a  $10^{-5}$ – $10^{-13}$  M range. In both cases, incubation was terminated by rapid filtration on GF/B filters treated with 0.1% (vol/vol) polyethylenimine followed by three washes with ice-cold 50 mM Tris-HCl, pH 7.4 on a Brandell cell harvester. Bound radioactivity was determined by scintillation counting. Scatchard and competition analyses were performed using the EBDA/Ligand program (G.A. McPherson, Biosoft, Cambridge, UK).

#### [ $^{35}\text{S}$ ] GTP $\gamma\text{S}$ binding studies

Stock [ $^{35}\text{S}$ ] GTP $\gamma\text{S}$  was diluted to 50 nM in 10 mM tricine pH 7.4, 10 mM DTT. Aliquots were stored at  $-80^{\circ}\text{C}$ . For each assay, 10  $\mu\text{g}$  of membrane protein was incubated in 50 mM Hepes, pH 7.4, 5 mM  $\text{MgCl}_2$ , 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% (wt/vol) BSA, 10  $\mu\text{M}$  GDP, 0.1 nM [ $^{35}\text{S}$ ] GTP $\gamma\text{S}$  and the appropriate ligand, in a final volume of 200  $\mu\text{l}$  for 2 h at  $4^{\circ}\text{C}$ . Non specific binding was determined in the presence of 10  $\mu\text{M}$  GTP $\gamma\text{S}$  and basal binding was assessed in the absence of agonist. Incubation was terminated by rapid filtration on  $\text{H}_2\text{O}$  presoaked GF/B filters followed by three washes with cold 50 mM Tris-HCl pH 7.4, 5 mM  $\text{MgCl}_2$ , 50 mM NaCl using a Brandell cell harvester. Bound radioactivity was determined by scintillation counting.  $\text{EC}_{50}$  values were determined using Prism software (GraphPad, San Diego, CA, USA).

#### Abbreviations

GPCR: G protein-coupled receptor, DAMGO: [D-Ala<sup>2</sup>, N-Me-Phe<sup>4</sup>, Gly<sup>5</sup>-ol]-enkephalin, CTOP: D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH<sub>2</sub>, DTT: dithiothreitol, HEK: human embryonic kidney, Gpp (NH) p: guanosine 5'-( $\beta,\gamma$ -imido) triphosphate, GTP $\gamma\text{S}$ : guanosine 5'-O-(3-thiotriphosphate), hMOR: human mu opioid receptor, PBS: phosphate-buffered saline, PTX: pertussis toxin, CAM: constitutively active mutant

#### Authors' contributions

KB carried out most of the experimental work

BLK participated in the design of the study and took active part in discussions

DM conceived the study and participated in the experimental part.

All authors read and approved the final manuscript.

#### Acknowledgements

We would like to thank Dr F. Pattus for financial support, Dr K. Befort for fruitful discussions and L. Snook for critical reading of the manuscript.

#### References

1. Massotte D, Kieffer BL: **A molecular basis for opioid action.** *Essays Biochem* 1998, **33**:65-77.
2. Costa T, Herz A: **Antagonists with negative intrinsic activity at  $\delta$  opioid receptors coupled to GTP-binding proteins.** *Proc Natl Acad Sci U S A* 1989, **86**:7321-7325.
3. Brys R, Josson K, Castelli MP, Jurzak M, Lijnen P, Gommeren W, Leyssen JE: **Reconstitution of the human 5-HT<sub>1D</sub> receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.** *Mol Pharmacol* 2000, **57**:1132-1141.
4. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Robin Ganellin C, Schwartz J-C, Arrang J-M: **High constitutive activity of native histamine H3 receptors regulates histamine neurons in brain.** *Nature* 2000, **408**:860-864.
5. Pauwels PJ, Wurch T: **Amino acid domains involved in constitutive activation of G protein-coupled receptors.** *Mol Neurobiol* 1998, **17**:109-135.
6. de Ligt RAF, Kourounakis AP, Ijzerman AP: **Inverse agonism at G protein-coupled receptors: (patho) physiological relevance and implications for drug discovery.** *Br J Pharmacol* 2000, **130**:1-12.
7. Mullaney I, Carr IC, Milligan G: **Analysis of inverse agonism at the delta opioid receptor after expression in rat I fibroblasts.** *Biochem J* 1996, **315**:227-234.
8. Szekeres PG, Traynor JR: **delta opioid modulation of the binding of guanosine-5'-O-(3-[ $^{35}\text{S}$ ] thio) triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.** *J Pharmacol Exp Ther* 1997, **283**:1276-1284.
9. Merkouris M, Mullaney I, Georgoussi Z, Milligan G: **Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells.** *J Neurochem* 1997, **69**:2115-2122.
10. Neilan CL, Akil H, Woods JH, Traynor JR: **Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.** *Br J Pharmacol* 1999, **128**:556-562.
11. Zaki PA, Keith DE, Thomas JB, Carroll FI, Evans CJ: **Agonist-, antagonist-, and inverse agonist-regulated trafficking of  $\delta$ -opioid receptor correlates with, but does not require, G protein activation.** *J Pharmacol Exp Ther* 2001, **298**:1-6.
12. Becker JAJ, Wallace A, Garzon A, Ingallinella P, Bianchi E, Cortese R, Simonin F, Kieffer BL, Pessi A: **Ligands for  $\kappa$ -opioid and ORL1**

- receptors identified from a conformationally constrained peptide combinatorial library. *J Biol Chem* 1999, **274**:27513-27522.
13. Burford NT, Wang D, Sadee W: **G-protein coupling of mu-opioid (OP3): elevated basal signalling activity.** *Biochem J* 2000, **348**:531-537.
  14. Wang D, Raehal KM, Bilsky EJ, Sadee W: **Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signalling in narcotic dependence.** *J Neurochem* 2001, **77**:1590-1600.
  15. Wang D, Surratt CK, Sadee W: **Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.** *J Neurochem* 2000, **75**:763-771.
  16. Liu J-G, Prather PL: **Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.** *Mol Pharmacol* 2001, **60**:53-62.
  17. Cotecchia S, Exum S, Caron MG, Lefkowitz RJ: **Regions of the alpha<sub>1</sub>-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function.** *Proc Natl Acad Sci U S A* 1990, **87**:2896-2900.
  18. Pei G, Samana P, Lohse M, Wang M, Codina J, Lefkowitz RJ: **A constitutively active mutant beta<sub>2</sub>-adrenergic receptor is constitutively desensitized and phosphorylated.** *Proc Natl Acad Sci U S A* 1994, **91**:2699-2702.
  19. Gether U, Ballesteros JA, Seifert R, Sansers-Bush E, Weinstein H, Kobilka BK: **Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility.** *J Biol Chem* 1997, **272**:2587-2590.
  20. McWhinney C, Wenham D, Kanwal S, Kalman V, Hansen C, Robishaw JD: **Constitutively active mutants of the alpha<sub>1A</sub>- and the alpha<sub>1B</sub>-adrenergic receptor subtypes reveal coupling to different signaling pathways and physiological responses in rat cardiac myocytes.** *J Biol Chem* 2000, **275**:2087-2097.
  21. Wade SM, Lan K-L, Moore DJ, Neubig RR: **Inverse agonist activity at the alpha<sub>2A</sub>-adrenergic receptor.** *Mol Pharmacol* 2001, **59**:532-542.
  22. Miserey-Lenkei S, Parnot C, Bardin S, Corvol P, Clauser E: **Constitutive internalisation of constitutively active angiotensin II AT<sub>1A</sub> receptor mutants is blocked by inverse agonists.** *J Biol Chem* 2002, **277**:5891-5901.
  23. Befort K, Zilliox C, Filliol D, Yue SY, Kieffer BL: **Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII.** *J Biol Chem* 1999, **274**:18574-18581.
  24. Cavalli A, Babey AM, Loh HH: **Altered adenylyl cyclase responsiveness subsequent to point mutations of Asp 128 in the third transmembrane domain of the delta-opioid receptor.** *Neuroscience* 1999, **93**:1025-1031.
  25. Décaillot FM, Befort K, Filliol D, Yue SY, Walker P, Kieffer BL: **Opioid receptor random mutagenesis reveals how a G protein-coupled receptor turns on.** *Nat Struct Biol* 2003, **10**:629-636.
  26. Li J, Huang P, Chen C, de Riel JK, Weinstein H, Liu-Chen L-Y: **Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression.** *Biochemistry* 2001, **40**:12039-12050.
  27. Li J, Chen C, Huang P, Liu-Chen L-Y: **Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation.** *Mol Pharmacol* 2001, **60**:1064-1075.
  28. Huang P, Li J, Chen C, Visiers I, Weinstein H, Liu-Chen LY: **Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp.** *Biochemistry* 2001, **40**:13501-13509.
  29. Tso PH, Wong YH: **Gz can mediate the acute actions of mu- and kappa-opioids but is not involved on opioid-induced adenylyl cyclase supersensitization.** *J Pharmacol Exp Ther* 2000, **295**:168-176.
  30. Leurs R, Smit MJ, Alewijnse AE, Timmerman H: **Agonist-independent regulation of constitutively active G-protein-coupled receptors.** *Trends Biochem Sci* 1998, **23**:418-422.
  31. Marki A, Monory K, Toth G, Krassnig R, Schidhammer H, Traynor JR, Roques BP, Maldonado R, Borsodi A: **Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [<sup>35</sup>S] GTPγS binding assays.** *Eur J Pharmacol* 1999, **383**:209-214.
  32. Claeysen S, Sebben M, Bécamel C, Eglen RM, Clark RD, Bockaert J, Dumuis A: **Pharmacological Properties of 5-Hydroxytryptamine<sub>4</sub> receptor Antagonists on Constitutive Active Wild-Type and Mutated Receptors.** *Mol Pharmacol* 2000, **58**:136-144.
  33. Wang D, Quillan JM, Winans K, Lucas JL, Sadee W: **Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding.** *J Biol Chem* 2001, **276**:34624-34630.
  34. Massotte D, Brillet K, Kieffer BL, Milligan G: **Agonists activate G<sub>i1</sub>α or G<sub>i2</sub>α fused to the human mu opioid receptor differently.** *J Neurochem* 2002, **81**:1372-1382.
  35. Ponimaskin EG, Heine M, Joubert L, Sebben M, Bickmeyer U, Richter DW, Dumuis A: **The 5-hydroxytryptamine (4a) receptor is palmitoylated at two different sites and acylation is critically involved in regulation of receptor constitutive activity.** *J Biol Chem* 2002, **277**:2534-2546.
  36. Chaturvedi K, Christoffers KH, Singh K, Howells RD: **Structure and regulation of opioid receptors.** *Biopolymers* 2000, **55**:334-346.
  37. Strange PG: **Mechanisms of inverse agonism at G-protein-coupled receptors.** *Trends Pharmacol Sci* 2002, **23**:89-95.
  38. Zaki PA, Keith DE, Brine GA, Carroll FI, Evans CJ: **Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?** *J Pharmacol Exp Ther* 2000, **292**:1127-1134.
  39. Chaipatikul V, Erickson-Herbrandson LJ, Loh HH, Law P-Y: **Rescuing the traffic-deficient mutants of rat mu-opioid receptors with hydrophobic ligands.** *Mol Pharmacol* 2003, **64**:32-41.
  40. Morello J-P, Petäjä-Repo UE, Bichet DG, Bouvier M: **Pharmacological chaperones: a new twist on receptor folding.** *Trends Pharmacol Sci* 2000, **21**:466-469.
  41. Petäjä-Repo UE, Hogue M, Laperrière A, Walker P, Bouvier M: **Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor.** *J Biol Chem* 2000, **275**:13727-13736.
  42. Jin H, Xie Z, George SR, O'Dowd BF: **Palmitoylation occurs at cysteine 347 and cysteine 351 of the dopamine D1 receptor.** *Eur J Pharmacol* 1999, **386**:305-312.
  43. Hawtin SR, Tobin AB, Patel S, Wheatley M: **Palmitoylation of the vasopressin V<sub>1A</sub> receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration.** *J Biol Chem* 2001, **276**:38139-38146.
  44. Holliday ND, Cox HM: **Control of signalling efficacy by Palmitoylation of the rat Y1 receptor.** *Br J Pharmacol* 2003, **139**:501-512.
  45. Moffett S, Adam L, Bonin H, Loisel TP, Bouvier M, Mouillac B: **Palmitoylated cysteine 341 modulates phosphorylation of the beta<sub>2</sub>-adrenergic receptor by the cAMP-dependent protein kinase.** *J Biol Chem* 1996, **271**:21490-21497.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

